{"id":"placebo-of-darolutamide","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Hypertension"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297185","moleculeType":"Small molecule","molecularWeight":"398.85"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in a decrease in the growth and spread of prostate cancer cells. By blocking the effects of androgens, darolutamide can help slow the progression of the disease.","oneSentence":"Darolutamide is a nonsteroidal antiandrogen that competitively inhibits the action of androgens, such as testosterone and dihydrotestosterone, at their receptor sites in various tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:07.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Nonmetastatic castration-resistant prostate cancer"}]},"trialDetails":[{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT05794906","phase":"PHASE3","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-04-03","conditions":"Biochemically Recurrent Prostate Cancer","enrollment":985},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":"Prostatic Neoplasms","enrollment":669},{"nctId":"NCT06120491","phase":"PHASE3","title":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-21","conditions":"Metastatic Castration-Sensitive Prostate Cancer","enrollment":1800},{"nctId":"NCT02799602","phase":"PHASE3","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":1306},{"nctId":"NCT04916613","phase":"PHASE3","title":"ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-04-19","conditions":"Prostate Cancer Metastatic","enrollment":300},{"nctId":"NCT02933801","phase":"PHASE2","title":"ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2017-03-31","conditions":"Prostate Cancer Metastatic, Prostate Cancer","enrollment":92},{"nctId":"NCT05116475","phase":"PHASE3","title":"Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases","status":"RECRUITING","sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","startDate":"2022-08-30","conditions":"Prostate Cancer","enrollment":152},{"nctId":"NCT05771896","phase":"PHASE3","title":"Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC","status":"WITHDRAWN","sponsor":"GenesisCare USA","startDate":"2023-09","conditions":"Metastatic Prostate Cancer","enrollment":""},{"nctId":"NCT04136353","phase":"PHASE3","title":"Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2020-03-31","conditions":"Prostate Cancer","enrollment":1100},{"nctId":"NCT04237584","phase":"PHASE3","title":"A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients","status":"TERMINATED","sponsor":"MANA RBM","startDate":"2020-06-30","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":23},{"nctId":"NCT02200614","phase":"PHASE3","title":"Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-09-12","conditions":"Prostate Cancer Non-Metastatic, Castration-Resistant","enrollment":1509},{"nctId":"NCT03704519","phase":"PHASE1","title":"Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-10-23","conditions":"Cerebrovascular Circulation","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":88,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of Darolutamide","genericName":"Placebo of Darolutamide","companyName":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","companyId":"association-pour-la-recherche-des-th-rapeutiques-innovantes-en-canc-rologie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darolutamide is a nonsteroidal antiandrogen that competitively inhibits the action of androgens, such as testosterone and dihydrotestosterone, at their receptor sites in various tissues. Used for Nonmetastatic castration-resistant prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}